Combination Therapy for Reducing Food Cravings

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for addressing excessive food cravings are largely ineffective, particularly for individuals with a long history of craving or food abuse, leading to severe long-term health issues such as obesity and related complications.

Innovation Solution

A combination therapy involving an opioid antagonist and an α-MSH activity enhancer, such as naltrexone and bupropion, is administered to antagonize opioid receptor activity and enhance melanocortin receptor activity, thereby reducing food cravings.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If psychological counseling and behavioral changes are used to treat food cravings, then the treatment approach is non-invasive and has no side effects, but the treatment is generally not very successful in individuals with long history of craving or food abuse

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the fundamental parameter of treatment approach from behavioral/psychological to pharmacological. By introducing specific compounds (opioid antagonists like naltrexone and alpha-MSH activity enhancers like bupropion), the treatment mechanism shifts from relying on patient behavior modification to using biochemical interventions that directly affect brain pathways involved in craving, thereby improving reliability for chronic cases

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent combines multiple pharmacological agents with different mechanisms of action (opioid antagonist + alpha-MSH enhancer) into a composite treatment regimen. This combination therapy addresses multiple aspects of the craving pathway simultaneously, enhancing overall treatment effectiveness compared to single-agent or non-pharmacological approaches

Inventive Principle:

Principle #40Composite materials

2Reliability

If pharmacological treatment is introduced to address persistent food cravings, then treatment effectiveness improves for severe cases, but the risk of side effects and drug interactions increases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses alpha-MSH activity enhancers as intermediary agents that work through the melanocortin receptor pathway to reduce cravings. This intermediary mechanism provides a more selective and controlled approach compared to broad-spectrum psychotropic medications, potentially reducing side effects while maintaining effectiveness for severe craving cases

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If combination therapy with opioid antagonist and alpha-MSH activity enhancer is administered, then food cravings are effectively reduced, but the treatment protocol complexity increases

Engineering Contradiction:

Improvecraving reduction efficacyVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges two pharmacological mechanisms (opioid antagonism and alpha-MSH enhancement) into a unified treatment protocol. By combining these agents, the treatment addresses both the reward pathway dysfunction and the homeostatic regulation aspects of craving, achieving synergistic effects that improve efficacy despite increased protocol complexity

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy effectively reduces food cravings, leading to weight loss and improved appetite suppression, as demonstrated by clinical trials using the Food Craving Inventory (FCI) scores and weight change assessments.

Implementation Method 1

administering a first compound and a second compound to the subject in an amount that is effective to reduce food craving, wherein the first compound is selected from an opioid antagonist and an anticonvulsant

Methodology Applied

Scientific EffectOpioid receptor antagonism:

Implementation Method 2

wherein the second compound is an α-MSH activity enhancer

Methodology Applied

Scientific EffectMelanocortin receptor activation:

Data Source

PatentUS20210267968A1Compositions And Methods For Reducing Food Cravings

Publication Date: 2021.09.02 NALPROPION PHARMACEUTICALS LLC

AI summary

Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an α-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.